Innate Pharma SA (IPHA) is a Marseille-based clinical-stage immuno-oncology company developing therapeutic antibodies and antibody-drug conjugates that harness the immune system against cancer. Its pipeline spans lacutamab, partnered with Sobi; monalizumab, licensed to AstraZeneca; and IPH4502, a proprietary Nectin-4 ADC carrying an exatecan payload.
Shares were trading at $1.10 in Wednesday's session, a decline of 17.29% from the prior close of $1.33. The direction was unambiguously lower and the stock printed a fresh 52-week low. The immediate driver was investor disappointment with the first detailed clinical dataset for IPH4502, released alongside a poster presentation at the 38th EORTC-NCI-AACR Symposium.
The dose-escalation study enrolled 76 patients with advanced solid tumors across six dose levels from 0.6 mg/kg to 3.6 mg/kg given every three weeks. The population was heavily pretreated, with a median of 3.5 prior lines of systemic therapy, and spanned more than ten tumor types.
The headline efficacy figure looked acceptable on the surface: at the maximum tolerated dose of 3.6 mg/kg, the objective response rate was 33% in non-urothelial tumors. That percentage, however, represented two responses among only six patients, a sample far too small to support firm conclusions about activity.
In the urothelial cancer cohort that the market regards as the program's commercial opportunity, 19 patients were enrolled, all previously treated with enfortumab vedotin. Fifteen were dosed at 2.4 or 2.8 mg/kg and four at 3.2 mg/kg, with none treated at the maximum tolerated dose. Three partial responses were reported, only one of them confirmed, against an unconfirmed disease control rate of 68.4%. Shrinkage was observed in the majority of patients, but the absence of any patients at the top dose level left the dose-response story incomplete.
Safety was the clear positive. Stomatitis was the only dose-limiting toxicity, occurring in 27.6% of patients overall and at grade 3 or above in 3.9%. There were no cases of febrile neutropenia, no hematologic dose-limiting toxicities and no signal of peripheral neuropathy. Grade 3 or higher treatment-emergent adverse events were reported in 43.4% of patients, and just 5.3% discontinued treatment.
Rather than advancing directly, the company said it is initiating a dose-optimization stage in second-line or later urothelial cancer, testing split dosing on days one and eight with mandatory prophylaxis to reduce stomatitis. The first patient is now planned for the first half of 2027. Investors who had positioned for a decisive efficacy signal found instead another year of waiting.
The selloff was amplified by how the stock had traded into the event. Shares climbed from $1.33 on November 3 to $1.59 on November 11, a gain of roughly 19%, as investors speculated on the data. Sell-side coverage stayed firmly constructive, with three analysts carrying buy-equivalent ratings and an average price target near $7, including targets of $9 and $7 set in early November. That gap between targets and the market price meant the readout carried a large share of the near-term valuation case, and a merely acceptable dataset was enough to force a reset.
The decline was concentrated in this single name rather than reflecting a broad repricing of the biotechnology sector, consistent with a company-specific binary event. Turnover was heavy against a thin baseline: the stock has averaged roughly 35,000 shares a day over three months and about 21,000 over the past ten sessions, and pre-market activity alone ran at a multiple of those figures.
Technically, the damage is significant. The stock broke to a new 52-week low beneath the prior floor of $1.17, extending a downtrend that has left it well under its 50-day moving average near $1.60 and its 200-day average near $1.70. With a float of roughly 69 million shares and short interest near 0.1% of float, there was no squeeze dynamic to cushion the fall; the move was driven by holders reducing exposure into a liquid, news-driven tape.
A score of 0 would describe no meaningful news and an ordinary move for the stock, while 100 would describe transformative news and a rare, extreme price swing. This event earns 64 out of 100. The verified news was substantive but not transformative: a detailed first-in-human dataset for the company's lead proprietary asset, delivered at a major oncology meeting, yet limited by tiny per-cohort numbers and a timeline that pushes the key efficacy work into 2027.
The price response was well outside normal behavior. The 17.29% decline was roughly five times the stock's average absolute daily move of about 3.4% over the past three months, and no session in that stretch produced a comparable swing, with the largest at roughly 14.9%. A moderately material catalyst paired with a rare, outsized move produces the mid-range score.
The immediate scheduled event is a key opinion leader webcast featuring Professor Yohann Loriot of Gustave Roussy, held today at 11:00 a.m. ET, where management will discuss the data and the development path. Investors will listen for the specific design and enrollment timeline of the urothelial dose-optimization study, including whether split dosing can preserve activity while reducing stomatitis.
Beyond IPH4502, the calendar is centered on 2027. Lacutamab, partnered with Sobi, is expected to dose its first patient in the Phase 3 TELLOMAK-3 trial in the first quarter of 2027, with an accelerated approval filing in Sézary syndrome targeted for the second half of the year. The AstraZeneca-led PACIFIC-9 Phase 3 study of monalizumab in non-small cell lung cancer is expected to read out in the first half of 2027.
Financial risk is manageable but not absent. Cash, cash equivalents and financial assets stood at €96.8 million at the end of September, a figure that includes a $75 million upfront payment from Sobi and gross proceeds of €30 million from an August private placement, supporting a runway into the first quarter of 2028. The principal uncertainties remain clinical, tied to small patient numbers, an unproven dose-response profile in urothelial cancer, and the possibility of further equity issuance before the next major readout.
Tickeron's Trending AI Robots page offers a curated view of the platform's automated trading strategies. Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions are surfaced in this section. Bots differ by strategy logic, timeframe, performance metrics and the symbols they trade, making the page a practical starting point for comparing approaches. Readers looking to see which models are working right now can explore the Trending AI Robots list for current rankings.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IPHA saw its Momentum Indicator move above the 0 level on November 16, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 113 similar instances where the indicator turned positive. In 92 of the 113 cases, the stock moved higher in the following days. The odds of a move higher are at 81%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for IPHA just turned positive on October 20, 2026. Looking at past instances where IPHA's MACD turned positive, the stock continued to rise in 39 of 50 cases over the following month. The odds of a continued upward trend are 78%.
Following a +6.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where IPHA advanced for three days, in 148 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
IPHA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 50-day moving average for IPHA moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IPHA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for IPHA entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.971) is normal, around the industry mean (3.592). P/E Ratio (-2.824) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (55.556) is also within normal values, averaging (442.120).
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. IPHA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IPHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment
Industry Biotechnology